Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront payment. This deal strengthens Innate Pharma's financial position, extending its cash runway through Q1 2028 despite a current ratio of 0.60, which indicates liquidity challenges. The partnership and improved financials support ongoing research and development in this clinical-stage biotech firm focused on cancer therapies.
Innate Pharma's recent financial update comes alongside a health sector breadth of 92 US stocks on Pluang, with 39 rising and 42 falling as of Sep 18, 2026 18:41 WIB. For readers following health stocks, notable movers include ADMA Biologics Inc at USD 9.15 with a 2.23% increase and 100% buy order activity, Citius Pharmaceuticals Inc at USD 0.60 with a 2.06% rise but 100% sell order activity, and Ginkgo Bioworks Holdings Inc at USD 7.98 up 1.79% with full buy order activity. This snapshot provides a market context for the sector on Pluang at the given time.
Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...
Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...
Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...
Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...
SpaceX's stock climbed 8% recently after reporting a 92% revenue increase to $7.81 billion, driven by Starlink and AI growth, but also posted a $541 million quarterly loss. The company aims for $100 billion annual revenue by year-end and a trillion-d...
